 The final item of business is a member's business debate on motion 7829, in the name of Claire Adamson, on pancreatic cancer awareness month. The debate will be concluded without any questions being put. Those members who wish to speak in the debate, please press their request to speak buttons now. I call on Claire Adamson to open the debate. Ms Adamson, seven minutes are there about, please. Thank you, Presiding Officer. Can I thank the members in the chamber tonight who will be contributing to what I believe is the first members' debate on pancreatic cancer awareness, and also to thank those who supported the most students during the debate this evening. I'd also like to welcome to the gallery the visitors this evening, ambassadors for pancreatic cancer UK and the family members and friends and indeed sufferers of pancreatic cancer. This is the start of a month of activities to raise awareness of this cancer. Presiding Officer, I am by no means an expert in this area. However, over the past years, I have been very privileged to meet pancreatic cancer ambassadors, families and sufferers and the many professionals who dedicate their lives to support treatment and research into this disease. I'd like to thank my parliamentary assistant, Nicola McManus, who first sparked my interest and informed me about this disease. Nicola's mother, Kathy's journey through this disease is all too familiar and heartbreaking. Having had her symptoms mistaken for many less serious conditions, it was a referral to a diabetic consultant who first raised the possibility about pancreatic cancer. Nicola's mum was already at stage 4 of the disease and died only a few short months later. I would also like to mention the family of William Begley of shots who also died very shortly after diagnosis in the late stages of the disease. Mr Begley's family has been very keen that their fathers and their own experience of the journey through pancreatic cancer has learning points and improvements at all levels of the care. They have worked very constructively and respectfully to have their concerns raised. Although I did not know Mr Begley having met his daughters, I think that they are living proof that he was an exceptional father and role model and, indeed, in their words, a fair man. Everyone here will have been touched in some way by this very cool and unforgiving cancer. The theme of this year's motion campaign from pancreatic cancer awareness once is demand better for patients and for survival. This is so important because we know that the survival rates are one of the poorest for any cancer. There is no early detection or screening available for pancreatic cancer, although we do know that early detection may be available as research is being done in this area currently. It is worth mentioning the most common symptoms this evening. To air those, it is really important that people understand that symptoms such as stomach and backache, unexplained weight loss and digestion, changes to bowel habits, including floating feces, other symptoms include loss of appetite, jaundice, yellowing of the skin or itchy skin, feeling and being sick, difficulty swallowing and recently diagnosed diabetes may all indicate the possibility of pancreatic cancer. It is very important that people suffering any of these symptoms should seek the advice of their GP. I mentioned that research for early detection is under way, but I also want to highlight some of the world-leading work that is being done in Scotland today with the support of Cancer Research UK. Cancer Research UK has identified pancreatic cancer as one of its four priorities because of its unmet need and its poor survival rates and the limited improvement in outcomes in the last decade. It has invested £10 million in the Precision Panc project. The project has been led by Professor Andrew Biancon at Cancer Research UK's Beatson Institute in Glasgow. Precision Panc aims to speed up recruitment and the enrolment of pancreatic cancer patients into clinical trials that are right for the individual patient. The researchers will use the genetic profile of each individual cancer to offer patients and their doctor a menu of trials that might benefit them. The three trials that are currently planned as part of the Precision Panc will be led by the Cancer Research UK clinical trials unit at the Beatson West of Scotland Cancer Centre. It will recruit a total of 650 patients in centres across the UK and patients will also be helped on to suitable clinical trials that are ready up and running. This is all about raising awareness of this cancer and this is so important because we know that in 2015 812 people in Scotland were diagnosed with pancreatic cancer and 749 of them are dead from that disease. It has the worst five-year survival rate of the 20 most common cancers at less than 7 per cent across the UK and that this figure has hardly changed in the last 40 years. Unless action is taken now, pancreatic cancer is set to become the fourth biggest cancer killer in the UK by 2026. I am very pleased that the Scottish Government is committed to funding the Precision Panc initiative and to support the University of Glasgow, which aims to personalise the treatment for pancreatic cancer, speed up the scientific discovery and improve survival rates. Nonetheless, that is just the start of what is needed. Pancreatic cancer has only attracted 1.9 out of the UK's research funding and this is something that many of the people in the gallery tonight want to see change both by their fundraising activities and by a recognition of how important that cancer is. This month, colleagues across the chamber and everyone can do their bit to highlight pancreatic cancer. We want to light up Scotland in purple. We want our towns to highlight the highlight buildings and historic buildings by lighting them up in purple, especially around 16 November, which is World Pancreatic Day and Pancreatic Cancer Day. I also want friends and colleagues to consider coming along at the end of the month and the 29th to the parliamentary event for Pancreatic Cancer UK. Both will be able to meet many of the clinicians involved and the researchers involved in trying to improve the outcomes for this disease. I ask everyone to wear purple, tell people why they are wearing purple and to talk about the disease and the symptoms, because it has only been made open and talking with one another, that we care for one another and ensure that we begin to tackle the disease. Deputy Presiding Officer, I would like to start by congratulating Claire Adamson on securing this important debate this evening. As a co-convener of our Parliament's cross-party group on cancer, I am very pleased that we are having this debate during Pancreatic Cancer Awareness Month. As the member has said, it is great to see so many members in purple. The fact that our parliamentary tie is purple also makes it a great opportunity for all the gentlemen in this Parliament to spend the next month highlighting the concerns. I look forward to lots of purple being displayed on local landmarks and across social media as we aim to increase knowledge and understanding of Pancreatic Cancer. I agree strongly with what Claire Adamson has said about the critical importance of raising awareness of Pancreatic Cancer as we focus on early diagnosis, which can improve a patient's chances of survival and therefore make much-needed progress in improving the current very low survival rates, which have remained at the same level now for the past four decades. It is a massive concern that 80 per cent of people with Pancreatic Cancer are not diagnosed until the cancer is at an advanced stage. Those who are diagnosed with Pancreatic Cancer are nearly six times less likely to live for five years than people with most other types of cancer in Scotland today. I am very pleased that, in 2017, we see the potential step change in the future treatment of Pancreatic Cancer following the biggest ever UK research investment by Cancer Research UK into the disease. Some £10 million has already been mentioned. As Claire Adamson said, PrecisionPank is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with Pancreatic Cancer, learn more about the disease and pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment. This world-leading research is led by Professor Andrew Byerkin and his team at Glasgow University. I know that all of us wish them great success in that. With some experts now warning that Pancreatic Cancer could become one of the UK's top four cancer killers by 2026, the outcome of PrecisionPank is of huge importance to all of us across the United Kingdom as well. Claire Adamson's motion rightly commends the role of pancreatic cancer charities and I join her in praising all of them and the role they play. Pancreatic Cancer UK is actively involved in our cancer CPG and does excellent work in raising the profile of issues around the disease. I want to pay particular tribute to two stakeholders involved in Pancreatic Cancer UK, Linda Murray and Kim Rowan, who attend the CPG and have a direct experience of the impact of pancreatic cancer on their families, members and friends. In preparing for today's debate, they highlighted the struggles of family members who have lost loved ones to the disease. Linda incredibly bravely produced a report on her late father, William Begley's journey through pancreatic cancer and I was pleased to be able to forward a copy of that to the Cabinet Secretary for Health and have some follow-up questions to try to suggest recommendations and improvements for care in Scotland. Families and friends of those who have lost loved ones to pancreatic cancer are very clear that there are significant improvements required to improve the current treatment of those with the cancer in Scotland. Specifically, they would like to see the Scottish Government take a lead in developing a multidisciplinary diagnostic centre approach for pancreatic cancer, consider targets for survival rates for less survivable cancers such as pancreatic cancer and be ready to copy the fast-track surgery model, which is currently being piloted south of the border if the evidence points to this actually being successful. They also want to see an end to delays of receiving MRI scans and the reduction in waiting times for chemotherapy treatment for patients with suspected and diagnosed pancreatic cancer. I would be grateful in summing up and closing this debate if the minister would give comments on where the Scottish Government currently at with these individual specific matters. In conclusion, I very much welcome today's debate and the opportunity for this Parliament to focus on pancreatic cancer for the first time. I hope that this debate and pancreatic cancer awareness month will help to get more people in communities right across our country talking about the disease and its potential symptoms and early diagnosis. There is much progress that needs to be made in the years ahead and I hope that MSPs from across the chamber will continue to speak about this and keep pressure on this Scottish Government to help to improve early detection, diagnosis and treatment. Thank you. Thank you very much Mr Briggs. A call when you're taught, we're followed by Tom Mason. Ms Todd, please. Thank you Presiding Officer and thank you to Claire Adamson for bringing this important topic to the chamber tonight. I'm pleased to make a contribution to this debate and I'm hopeful that together we will help to raise awareness of this disease. Pancreatic cancer charities have been working tirelessly to make their campaign demand better for patients, for survival, known throughout the UK. The colour purple is integral to spreading knowledge and awareness of the cancer. I did hope to wear a purple jacket today, but I had a laundry crisis, apologies. Charities are using the phrase turn it purple to encourage people to get involved in the awareness campaign and last year we saw the Kelpie's turn purple in November along with many other landmarks as part of the campaign. Over the last 40 years, improvements in prevention, detection and treatment have revolutionised cancer medicine and survival has doubled, but progress, as we've heard, has not advanced equally for all forms of the disease. Pancreatic cancer hasn't seen much improvement at all and the five-year survival rates are frankly dire at just over 3 per cent in Scotland. That is the worst survival outcome for any of the 21 most common cancers and it hasn't improved in almost 50 years. The biggest problem is the fact that 80 per cent of the people who are diagnosed with pancreatic cancer are diagnosed at an advanced stage when it's too late for surgery, which is currently the only potential cure. Most patients die within three to six months following diagnosis. I'm very grateful to Cancer Research UK for their pioneering project, PrecisionPank, which aims to speed up the recruitment and enrolment of pancreatic cancer in patients to clinical trials, as we've heard. Those trials will be right for the individual patient and they are also tripling their investment in research. I really hope that their efforts pay dividends. That isn't a rare disease. Pancreatic cancer is currently the fifth biggest cancer killer in the UK. As we've heard from Miles Briggs, if trains continue, it's set to overtake breast cancer as the fourth most common cancer killer by 2030. That's partly because survival rates are improving for everything else. There's currently no screening or early detection tests for pancreatic cancer, although summer in development and, as with all cancer, early detection improves outcomes. Most of us don't even know where our pancreas is. It's right here, tucked in about your liver and stomach. There's also research evidence that we can't recognise the symptoms of this disease, so like Claire, I'm going to go over them. The first noticeable symptoms of pancreatic cancer are often pain in the back or stomach area, which might come and go at first. It's often worse when you lie down or after you've eaten. Unexpected weight loss and jaundice. The most obvious sign of jaundice is yellowing of the skin and the whites of the eyes, but it also turns your urine dark yellow or orange and your stools go pale-coloured. There have been some risk factors identified, and some of them, like your genes, there's not much that you can do to change, but about one in three cases of pancreatic cancer is associated with using cigarettes, cigars or chewing tobacco. As ever, I feel obliged to encourage anyone out there who is still smoking to try and stop and keep on trying until you do stop. It is the single most effective thing that you can do to improve your health. I, too, was contacted by Linda Murray and Kim Rowan. They did a great job and they asked me to participate in this debate in order to raise awareness in the general population, in the medical community and amongst decision makers. Linda, in particular, wrote very movingly about her dad's experience of care and his journey through pancreatic cancer. I've also had a close friend affected. I hope that I have done the issue justice for you all, and I hope that our efforts will continue to lead to an improvement in research, detection and care in the future. Thank you very much. I call Tom Mason to be followed by Colin Smyth. Mr Mason, please. Thank you, Presiding Officer. I'm profoundly grateful to Claire Adamson for bringing his motion forward today. Too many families in Scotland are affected by cancer. Too many lives are turned upside down. Too many people suffering pain and loss. No doubt all of us in this Parliament know that people are affected in some way. I have had my own personal experience with this as well, having been successfully treated for prostate cancer, a journey that was not pleasant. I know that pancreatic cancer is even worse. Unfortunately, however, due to the lack of symptoms until late stage and the difficulty in detection and diagnosis, pancreatic cancer remains among the most aggressive types of cancer and one of the most difficult to treat. Mortality rates remain among the worst, with five years of rather in the low single digits. The world pancreatic cancer coalition estimates that by 2020 we will see 418,000 new diagnoses worldwide. It is clear that we must do more. Members across the chamber will be familiar with the many different statistics that illustrate the extent of the task ahead. We have had many of them said and outlined already. Instead of going through them individually, I want to talk about the more human side of this problem. I want to pay tribute to the pancreatic cancer survivors, of which there are unfortunately very few, who have battled so courageously in the face of overwhelming odds and the families that support them in the worst circumstances imaginable. I want to do whatever I can to reassure those with the recent diagnosis that we will never stop trying to find new ways to improve pallent of care and ultimately accure. Our scientific community in Scotland and around the world will continue their work and we must support them. Research has been done in Glasgow University as a great example of this and I, of course, wish them well and I hope for the earliest success. However, the task of treating this cancer is not one that can be accomplished by science alone. The public have heard and have a vital role to play as well. This is precisely why events such as pancreatic cancer awareness months are so important. Increased awareness can have a direct and tangible impact on detection of the disease for earlier than we are doing today. It can mean the difference in life and death. In that respect, I am pleased to play tribute to the demand better campaign. It is no small achievement to bring together more than 60 organisations across six continents in pursuit of this common goal. It is imperative that campaigns like this continue to grow in the years ahead. I would support any efforts that we make in this Parliament to help. We need to encourage everyone, not just to be aware of what the symptoms are, but to seek medical assessment whenever they appear, even if they seem trivial. Presiding Officer, we must be resilient and set alongside patriotic cancer sufferers and their families. We must recognise that if we want to lessen the impact of the disease that has on our society in the years to come, the earliest possible detection is vitally important. It begins with us talking about it, sharing the experience of those who have been affected in the hope that, in future days, we can diagnose and successfully treat the disease before it is simply too late. I also echo the thanks of others to Clare Adamson for her motion, which has provided MSPs with the opportunity to help to raise awareness of pancreatic cancer. I would also like to welcome our visitors to the public gallery and to congratulate all charities and our supporters for the fantastic work that they do during pancreatic cancer awareness month, World Pancreatic Cancer Day and all year round. Each year, campaigns such as Turn It Purple do crucial work to raise awareness and stimulate discussion about pancreatic cancer. This year's World Pancreatic Cancer Day is on 16 November, and its theme, as Clare Adamson said, demand better for patients for survival, provides an opportunity to raise awareness and discuss the key issues surrounding pancreatic cancer and its impact across the world. With more than 60 member organisations from 27 different countries, the World Pancreatic Cancer Coalition and its members' organisations are doing some outstanding work in specific countries but also on an international scale. That work is vital to the lives of so many. Every day, more than 1,000 people worldwide are diagnosed with pancreatic cancer, and around 985 people die from it each day. The picture in Scotland is equally worrying. In 2015, 812 people in Scotland were diagnosed with pancreatic cancer and 749 people died as a result of it. The number of incidents of pancreatic cancer increased significantly between 2005 and 2015, rising by 11.9 per cent. The lifetime risk of developing pancreatic cancer is now one in 80 for men and one in 83 for women. Before today's debate, I contacted a constituent of mine, Tom Pickier, from Ringford and Galloway. Tom sadly lost his wife, Isabel, last year to what he described as this insidious disease. Since then, he has been determined to raise awareness and memory of Isabel as well as raised badly needed funds for the charities carrying out the important work that I and others have mentioned during today's debate. Tom has already raised thousands of pounds for pancreatic cancer Scotland, and he urged me to use today's debate to encourage as many people as possible to fundraise for PCS and other charities to help to find ways to detect this appalling condition as early as possible. Tom potted out to me that, in Scotland, pancreatic cancer remains one of the least-survivable cancers with a relative five-year survival rate of less than 4 per cent. He stressed that early diagnosis and treatment is the key to improving those mortality rates. There is therefore an urgent need to raise awareness about pancreatic cancer and its symptoms. However, symptoms are often late recurring and nonspecific, so we cannot rely just on raising awareness to improve detection. As the motion notes, there are currently no screening or early detection tests for pancreatic cancer, and I would like to voice my support for the on-going work that is being done to develop such a test. There is valuable research taking place, looking into how biomarkers and scans might be used in the screening process, and it is vital that that work receives the support and funds that it needs. As is all too often the case, pancreatic cancer disproportionately affects the worse off in our societies. Both prevalence and mortality are correlated with deprivation, with someone in the most deprived area being 31 per cent more likely than someone from the least deprived area to suffer from pancreatic cancer and 32 per cent more likely to die from it. It is vital that we gain a better understanding of the risk factors contributing to this cancer in order to take a holistic approach to reducing incidence and mortality. Smoking has been identified as a potential cause of pancreatic cancer, and factors such as age, weight and family history are all thought to contribute. However, there remains a great deal more to be done in this regard, and a recent ICD report on cancer in Scotland stated that the causes of pancreatic cancer are still poorly understood. Getting to grips with the causes and risk factors underpinning this cancer will not only help to identify those who are high at risk but will better allow us to take more preventative approach and work to address the underlying causes of pancreatic cancer. In the meantime, I hope that today's debate and the work of people like Tom, those in our gallery and our invaluable cancer charities has played a small part in raising awareness of this condition, which sadly impacts on far too many of our constituents. I thank you for allowing me to speak in this debate today to mark world pancreatic cancer day on the 16th of November and pancreatic cancer awareness month. I congratulate Claire Adamson on securing this debate today. I have a particular interest in this disease as my late wife charity died of pancreatic cancer on 29 December 2049. Some longer serving members may remember her, and she was a classic victim of pancreatic cancer as she died following an exploratory operation without recovering consciousness and not knowing that she had this dreadful disease. Then, as now, there was no screening or early detection test. Notwithstanding her pronounced jaundice, her GP never considered that this classic symptom might point to her having this disease. Even if she had survived this operation, she would have died within three months, as her cancer was so advanced by the time she got to the operating theatre. Today, I am taking part in this debate and part as a heartfelt tribute to her memory, but also to support the campaign to raise awareness of this disease. It is simply not acceptable that pancreatic cancer is said to become the fourth biggest cancer killer in the UK by 2026, yet currently pancreatic cancer research only attracts 1.9 per cent of UK cancer research spending, as others have said. It is simply not acceptable that, of the 812 people diagnosed with pancreatic cancer in Scotland in 2015, 749 of them died that year. It is not acceptable that only 7 per cent of those diagnosed survive longer than five years. I, too, welcome today the Scottish Government's funding of the Precision Panc initiative, based at Glasgow University and the Beatson, which aims to personalise treatment for pancreatic cancer, speed up scientific discovery, and improve survival rates. I wish those researchers every success. I fully support more research into pancreatic cancer. I fully support the good work of Cancer Research UK in its fundraising to tackle all cancers, so that, in the future, as few families as possible, do not lose their loved ones to pancreatic and other cancers. Wish me luck as I go for my own pancreatic MRI scan on 16 November. Thank you very much, Mr Scott. That was tough to do, but I do recall your wife in those circumstances as one of the early members of Parliament. I now call on the minister, Eileen Campbell, to wind up. Seven minutes are thereabouts, please. Thank you, Presiding Officer. It gives me great pleasure to close tonight's debate, and I want to thank Clare Adamson for securing it and for articulating very emotively her reasons for doing what she can to raise awareness of this incredibly cruel condition, and, as the campaign states, to demand better. I would like to pay special tribute to John Scott, who was very brave to pay tribute to his late wife. It is not easy to do, and I think that sometimes, Presiding Officer, those debates that are often missed by the press, often are when you hear members speak the most powerfully and the most movingly, and again just pay tribute to John for contributing to this debate. It's very difficult to follow him, because I think that everyone's been touched by how he made his case. I'd also like to wish him well for his own test that's about to come up. I'd also like to welcome all from pancreatic cancer UK to the chamber and to all who have the condition or who have a loved one impacted your presence. It's incredibly important so to your stories, your awareness-raising and all the work that you do and the effort that you put in to make him sure that people know about this condition. I'd also like to pay tribute to Nicholas Mum and William Begley to ensure that their experience can go on to generate the improvements that we need to see happen across the country. The Scottish Government recognises the damaging impact of all cancers, including pancreatic cancer, on individuals, their families and their friends. However, we should recognise that there has been some progress over the past 10 years overall. Age-adjusted cancer mortality rate in Scotland has reduced by 11 per cent, a significant improvement, thanks to the efforts of people across the NHS and the third sector. I want to pay tribute and thank sincerely all those people who work tirelessly across the country delivering our health and social care services and those who raise awareness of such terrible diseases such as pancreatic cancer. However, we absolutely recognise that there are a small number of cancers, including pancreatic cancer, where survival rates remain stubbornly low in part, as members have said, because of late detection. Despite all our efforts and the improvements that we have seen in the UK and Scotland, there are still behind some other countries in terms of cancer survival rates for a number of tumour types. In particular for tonight's debate, in pancreatic cancer, we still need to bring about much-needed improvement. In March 2016, the Scottish Government unveiled its beating cancer ambition and action strategy, which serves as a blueprint for the future of cancer services in Scotland. The Scottish Government is acutely aware that early detection of all cancers, including pancreatic cancer, is crucial. The earlier that cancer can be diagnosed, the better the chance of a positive outcome. The cancer strategy will deliver 100 million of investment over the coming years to improve the prevention, the detection, the diagnosis, treatment and aftercare for all those who are affected by cancer. Supporting those ambitions is our 41 million detect cancer early programme, which, over the past five years, has increased diagnostic capacity across Scotland, as well as working to increase awareness of the signs and symptoms of cancer. Next year, the programme will focus on the overall benefits of early detection for all cancers and aims to encourage anyone with any concerns or changes to their body to visit their GP. I will certainly instruct my officials to meet with colleagues from the pancreatic cancer charities to discuss how we can support awareness messages through our VC strategy and social media and digital channels and any other channels that are appropriate. Of course, we would extend that, also if Ms Adamson would like to, to be part of that meeting. Another area of work that the Scottish Government has supported in order to improve diagnosis is the Scottish referral guidelines for suspected cancer, which were updated in 2014. Those include a specific section on pancreatic cancer and are intended to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist, including all the tell-tale signs that Clare Adamson, Mary Todd and others have outlined, with a clear instruction in those referral guidelines to have a low threshold for considering further investigation or referral because of the detection difficulties that we know exist with this cancer. Once referral is made, we need to ensure that no one has to wait longer than they should to receive a diagnosis and then, if needed, treatment of their cancer. That is why the cabinet secretary announced the formation of a new ministerial cancer performance delivery group. That group will focus on driving forward improvements and waiting times for diagnosis and treatment for cancer patients in Scotland. It is backed by an additional £1 million investment to help to address shortfalls and capacity in some areas. That is an addition to the £4.85 million of investment that was made in 2017 to support improvement in diagnostic scopes and imaging capacity for suspected cancer patients. It is also important that we aim to prevent cancers from occurring in the first place. I think that that was made by Colin Smyth. We know that smoking and obesity can be contributing factors in developing pancreatic cancer. As we all know, Scotland has done much over the past years to reduce the harms from preventable public health approaches. We have taken forward strategic approaches to tackle drinking, smoking and, of course, one that will have an indirect impact on this debate, the newly launched consultation on diet and obesity that we made public last meet last week. However, most members recognised the difficulty in diagnosing pancreatic cancer early. The symptoms are often nonspecific and can mean that people present very late to their GP. It is therefore important that we have a good understanding of the type of tumour to enable NHS Scotland colleagues to treat it more effectively. The Scottish Government has made available, via the chief science office, more than £700,000 to support precision panc along with £10 million from Cancer Research UK. That investment will help to improve our understanding of the tumour type, hopefully leading to more effective treatments. At that point, I welcome the increased focus from Cancer Research UK on those less-survivable cancers, such as pancreatic cancer. I hope that the increased research capacity helps to improve outcomes for all those who are affected by the cancer. I would also like to know that researchers can apply to the Scottish Government's CSO for funding, and that applications investigating the diagnosis and treatment of pancreatic cancer would be very welcome. In direct response, however, to Miles Briggs's point about the fast tract referral and treatment trials that are happening in England, it is important to know that it will be at least two years before the outcomes of the pilot are known. However, there are processes in place via National Services Scotland and our national cancer clinical services group to ensure that any new emerging evidence from those studies are considered when developing services in Scotland. To close, we absolutely know that we need to raise awareness about this condition. We also know that we need to continue with the research, and we also need to be mindful of the correlation with cancer prevalence and inequalities that are faced by too many of our communities. To make the improvements, we also need to be mindful of the stories of those feeling the pain of pancreatic cancer, whether it is them themselves who have been diagnosed or whether it has been a loved one who has had this diagnosis. We demand better for them, and in the words of Linda Murray, we will keep on advocating to ensure that other people get a fairer chance of survival. I again pay tribute to Clare Adamson for bringing this important debate to the chamber and also to John Scott and others who have spoken very powerfully about the impact that this cruel disease can have on the people they know, whether they are constituents or loved ones, and hopefully we can work together in terms of research, building a capacity to make sure that we can bring about the improvements that we need that have been a long time coming. Thank you. Thank you. That concludes the debate, and I commend all members who took part in the debate for their speeches, and I close this meeting of Parliament.